Bioasis Technologies (BIOAF) 1.0924 $BIOAF
WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series
biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.
biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company"
announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization.
biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.
biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Marketwire - Mon Jun 16, 8:02AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company" is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital" effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program.
biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend
Marketwire - Mon Mar 17, 8:05AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
biOasis Technologies to list its stock in OTCQX Marketplace in the US
M2 - Tue Feb 25, 6:11AM CST
biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) said on Monday that it has upgraded the listing of its stock to the highest tier of the off-market, OTCQX, under the symbol BIOAF.
biOasis to Begin Trading on OTCQX(R) Marketplace in the U.S.
Marketwire - Mon Feb 24, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
Marketwire Canada - Mon Feb 24, 8:02AM CST
biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis Technologies Begins Trading on OTCQX®
PR Newswire - Mon Feb 24, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that biOasis Technologies Inc. (TSX.V: BTI; OTCQX: BIOAF), a Vancouver-based biopharmaceutical company focused on developing a proprietary brain delivery platform ("Transcend" to enable existing and create new drugs that address unmet medical needs in the treatment of brain diseases, has been approved to trade on OTCQX®, the best marketplace with qualified companies.
Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis
M2 - Thu Feb 13, 10:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqg5p5/global_lithium) has announced the addition of the "Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis" report to their offering. Lithium-ion battery demand is expected to see a robust growth in the forecast period. This is due to its increasing demand across various application sectors such as automotive, wind, electronics, industrial and military. The market is currently driven by its usage in automotive sector in HEVs, trains and trams. Lithium-ion batteries can be differentiated primarily based on their functionality. The application of lithium-ion battery alongside other batteries is expected to increase, and lithium-ion batteries are expected to emerge as a replacement for lead acid batteries in the coming years. This report has been segmented by material type, by application and by geography. It also includes the drivers, restraints and opportunities (DROs), Porter's five forces analysis and value chain of the lithium-ion battery market. The study highlights current market trends and provides the forecast from 2013 to 2019. Scope of the Report Material Type - Cathode - Anode - Electrolytic Solution - Others (Binders, Separators etc) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Lithium-Ion Battery Market Analysis, By Material Type Chapter 5 Lithium-Ion Battery Market Analysis, By Application Chapter 6 Lithium-Ion Battery Market Analysis And Forecast, By Geography Chapter 7 Company Profiles - A123 Systems Llc - Automotive Energy Supply Corporation (Aesc) - China Bak Battery Co Ltd - Ga Yuasa Corporation - Hitachi Chemical Co Ltd - Johnson Controls, Inc - Lg Chem Power, Inc - Panasonic Corporation - Samsung Sdi Co Ltd - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/zq...al_lithium
WSA Talks to Two Dual-Listed Companies Making Waves
Marketwire - Thu Aug 21, 1:00PM CDT
Wall Street Analyzer's CEO Interview Series
biOasis issues up to 1.6m units in non-brokered private placement
M2 - Mon Aug 11, 3:29AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) reported on Friday the launch of a non-brokered private placement of up to 1,600,000 units.
biOasis Announces Non-Brokered Private Placement
Marketwire - Fri Aug 08, 8:10PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF)(the "Company"
announces a non-brokered private placement of up to 1,600,000 units (each a "Unit" at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant" . Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $1.20 per share for a period of twelve months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $1.40 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. Certain directors and officers of the Company intend to acquire the Units under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61 -101 Protection of Minority Security Holders in Special Transactions ("MI 61-101" . The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, will exceed 25% of the Company's market capitalization. biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
Marketwire - Fri Jul 25, 8:31AM CDT
BIOASIS TECHNOLOGIES INC. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose.
biOasis Appoints New Chief Financial Officer and Corporate Secretary
Marketwire - Fri Jun 20, 6:30PM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of British Columbia Faculty of Law who also has a strong accounting background, having been controller and business manager of a major magazine publishing enterprise for over 20 years. Ms. Dalling currently works with various reporting companies, providing legal, accounting and administration services.
biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Marketwire - Mon Jun 16, 8:02AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI) (OTCQX: BIOAF) (the "Company"
is pleased to announce that is has retained Gale Capital Corporation ("Gale Capital" effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program. biOasis awarded patent allowances for Lysosomal Storage Disease therapeutic in Europe and Canada
M2 - Fri Mar 28, 3:37AM CDT
Biopharmaceutical company biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) disclosed on Thursday the receipt of notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Marketwire - Thu Mar 27, 8:03AM CDT
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has received notices of allowance from the European and Canadian Patent offices for its patent application titled, "Use of P97 as an Enzyme Delivery System for the Delivery of Therapeutic Lysosomal Enzymes".
biOasis Enters Into a License Agreement With Medimmune for Second Generation Versions of biOasis's Transcend
Marketwire - Mon Mar 17, 8:05AM CDT
BIOASIS TECHNOLOGIES INC. (OTCQX: BIOAF)(TSX VENTURE: BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
biOasis Technologies to list its stock in OTCQX Marketplace in the US
M2 - Tue Feb 25, 6:11AM CST
biOasis Technologies (TSX VENTURE:BTI)(Other OTC:BIOAF) said on Monday that it has upgraded the listing of its stock to the highest tier of the off-market, OTCQX, under the symbol BIOAF.
biOasis to Begin Trading on OTCQX(R) Marketplace in the U.S.
Marketwire - Mon Feb 24, 8:05AM CST
biOasis Technologies Inc. (TSX VENTURE: BTI)(OTCQX: BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
Marketwire Canada - Mon Feb 24, 8:02AM CST
biOasis Technologies Inc. (TSX VENTURE:BTI)(OTCQX:BIOAF) a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off-market, OTCQX(R) under the symbol BIOAF.
biOasis Technologies Begins Trading on OTCQX®
PR Newswire - Mon Feb 24, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that biOasis Technologies Inc. (TSX.V: BTI; OTCQX: BIOAF), a Vancouver-based biopharmaceutical company focused on developing a proprietary brain delivery platform ("Transcend"
to enable existing and create new drugs that address unmet medical needs in the treatment of brain diseases, has been approved to trade on OTCQX®, the best marketplace with qualified companies. Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis
M2 - Thu Feb 13, 10:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/zqg5p5/global_lithium) has announced the addition of the "Global Lithium Ion Battery Market to 2019: Cathode, Anode & Electrolytic Solution Analysis" report to their offering. Lithium-ion battery demand is expected to see a robust growth in the forecast period. This is due to its increasing demand across various application sectors such as automotive, wind, electronics, industrial and military. The market is currently driven by its usage in automotive sector in HEVs, trains and trams. Lithium-ion batteries can be differentiated primarily based on their functionality. The application of lithium-ion battery alongside other batteries is expected to increase, and lithium-ion batteries are expected to emerge as a replacement for lead acid batteries in the coming years. This report has been segmented by material type, by application and by geography. It also includes the drivers, restraints and opportunities (DROs), Porter's five forces analysis and value chain of the lithium-ion battery market. The study highlights current market trends and provides the forecast from 2013 to 2019. Scope of the Report Material Type - Cathode - Anode - Electrolytic Solution - Others (Binders, Separators etc) Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Lithium-Ion Battery Market Analysis, By Material Type Chapter 5 Lithium-Ion Battery Market Analysis, By Application Chapter 6 Lithium-Ion Battery Market Analysis And Forecast, By Geography Chapter 7 Company Profiles - A123 Systems Llc - Automotive Energy Supply Corporation (Aesc) - China Bak Battery Co Ltd - Ga Yuasa Corporation - Hitachi Chemical Co Ltd - Johnson Controls, Inc - Lg Chem Power, Inc - Panasonic Corporation - Samsung Sdi Co Ltd - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/zq...al_lithium
